WO2022190626A1 - Sn-38誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 - Google Patents
Sn-38誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 Download PDFInfo
- Publication number
- WO2022190626A1 WO2022190626A1 PCT/JP2022/001163 JP2022001163W WO2022190626A1 WO 2022190626 A1 WO2022190626 A1 WO 2022190626A1 JP 2022001163 W JP2022001163 W JP 2022001163W WO 2022190626 A1 WO2022190626 A1 WO 2022190626A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- mmol
- salt
- present
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 108
- 150000003839 salts Chemical class 0.000 claims abstract description 56
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 11
- 125000000962 organic group Chemical group 0.000 claims abstract description 9
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims abstract description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 7
- 229930195735 unsaturated hydrocarbon Natural products 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 11
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 abstract description 22
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- -1 5-(1,2-dithiolan-3-yl)pentanoyloxy group Chemical group 0.000 description 50
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 20
- 150000002430 hydrocarbons Chemical group 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 125000000217 alkyl group Chemical group 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
- 239000006185 dispersion Substances 0.000 description 16
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 235000019260 propionic acid Nutrition 0.000 description 13
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 13
- 125000004423 acyloxy group Chemical group 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000002245 particle Substances 0.000 description 8
- 235000002597 Solanum melongena Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- KYNFOMQIXZUKRK-UHFFFAOYSA-N 2,2'-dithiodiethanol Chemical compound OCCSSCCO KYNFOMQIXZUKRK-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical group [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 238000002250 neutron powder diffraction Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Chemical group 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- OQURWGJAWSLGQG-UHFFFAOYSA-N 1-isocyanatopropane Chemical compound CCCN=C=O OQURWGJAWSLGQG-UHFFFAOYSA-N 0.000 description 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 2
- PHIITBMJGQIRSS-UHFFFAOYSA-N 2-(1-hydroxypropan-2-yldisulfanyl)propan-1-ol Chemical compound OCC(C)SSC(C)CO PHIITBMJGQIRSS-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- 229960001237 podophyllotoxin Drugs 0.000 description 2
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WLAMNBDJUVNPJU-SCSAIBSYSA-N (R)-2-methylbutyric acid Chemical compound CC[C@@H](C)C(O)=O WLAMNBDJUVNPJU-SCSAIBSYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-BYPYZUCNSA-N (S)-2-methylbutyric acid Chemical compound CC[C@H](C)C(O)=O WLAMNBDJUVNPJU-BYPYZUCNSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- DIZKLZKLNKQFGB-UHFFFAOYSA-N 1-methylcyclopropane-1-carboxylic acid Chemical compound OC(=O)C1(C)CC1 DIZKLZKLNKQFGB-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- KVVDRQDTODKIJD-UHFFFAOYSA-N 2-cyclopropylacetic acid Chemical compound OC(=O)CC1CC1 KVVDRQDTODKIJD-UHFFFAOYSA-N 0.000 description 1
- AYEGPMGNMOIHDL-UHFFFAOYSA-N 2-methylcyclopropane-1-carboxylic acid Chemical compound CC1CC1C(O)=O AYEGPMGNMOIHDL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- YYSCJLLOWOUSHH-UHFFFAOYSA-N 4,4'-disulfanyldibutanoic acid Chemical compound OC(=O)CCCSSCCCC(O)=O YYSCJLLOWOUSHH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000002197 cyclohepta-2,4,6-trienyl group Chemical group 0.000 description 1
- 125000002100 cyclohexa-1,3-dienyl group Chemical group [H]C1([*])C([H])=C([H])C([H])=C([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- RRTCPFRSMPSGHY-UHFFFAOYSA-N ethoxyethane;1-methoxy-2-(2-methoxyethoxy)ethane Chemical compound CCOCC.COCCOCCOC RRTCPFRSMPSGHY-UHFFFAOYSA-N 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNHVTXYLRVGMHD-UHFFFAOYSA-N n-butyl isocyanate Chemical compound CCCCN=C=O HNHVTXYLRVGMHD-UHFFFAOYSA-N 0.000 description 1
- 125000006610 n-decyloxy group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000006609 n-nonyloxy group Chemical group 0.000 description 1
- 125000006608 n-octyloxy group Chemical group 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- An object of the present invention is to provide new organic nanoparticles and new compounds for composing the organic nanoparticles.
- the present invention aims to provide organic nanoparticles capable of selective drug release in tumor tissue.
- GSH glutathione
- Section 1 A compound represented by the following general formula (1) or a salt thereof.
- R 1 is the same or different and represents hydrogen, a hydroxy group or a carbon-containing organic group.
- R 2 is the same or different and represents an optionally substituted ethylene group or trimethylene group.
- Section 4 A nanoparticle comprising the compound or a salt thereof according to any one of Items 1 to 3.
- a medicament comprising the compound or salt thereof according to any one of Items 1 to 3 or the nanoparticles according to Item 4.
- Item 6. The medicament according to Item 5 for preventing or treating cancer.
- Item 7. A method for producing nanoparticles, comprising the step of injecting a water-miscible organic solvent solution of the compound according to any one of items 1 to 3 or a salt thereof into water.
- Item 8 A method for preventing or treating cancer, comprising administering an effective amount of the compound or salt thereof according to any one of Items 1 to 3 or the nanoparticles according to Item 4 to a subject in need thereof.
- Item 9 Use of the compound or salt thereof according to any one of Items 1 to 3, or the nanoparticles according to Item 4, for manufacturing a preventive or therapeutic agent for cancer.
- Item 10. The compound or salt thereof according to any one of Items 1 to 3 or the nanoparticle according to Item 4 for use in the prevention or treatment of cancer.
- organic nanoparticles capable of selective drug release in tumor tissue can be provided.
- Test Example 1 shows an SEM photograph of nanoparticles of Compound B in Example 1.
- FIG. 10 shows SEM photographs of SNC4DC nanoparticles in Example 9 and results of changes in particle size over time.
- FIG. 2 shows the results of an in vivo antitumor activity test in Test Example 2.
- FIG. 5 shows changes in body weight over time in each test group of Test Example 2.
- R 1 is the same or different and represents hydrogen, a hydroxy group or a carbon-containing substituent.
- R 2 is the same or different and represents an optionally substituted ethylene group or trimethylene group.
- carbon-containing organic groups include organic groups having 1 to 20, preferably 2 to 17 carbon atoms.
- R 4 represents a C2-C10 alkyl group, a C3-C10 cycloalkyl group, a C4-C10 cycloalkyl-alkyl group or a C4-C10 alkyl-cycloalkyl group), etc. is mentioned.
- alkyl group refers to a linear or branched saturated hydrocarbon group, such as methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, C1-C10 alkyl groups such as sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, n-hexyl group, n-heptyl group, n-octyl group, n-nonyl group and n-decyl group; C1-C8 alkyl groups are preferred, C1-C6 alkyl groups are more preferred, and C1-C3 alkyl groups are more preferred.
- alkoxy group includes an alkoxy group in which the alkyl portion is the aforementioned alkyl group. More specifically, alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, and n-pentyloxy.
- the acyloxy group refers to a carbonyloxy group to which a linear or molecular chain (preferably linear) saturated hydrocarbon is bonded, for example, an acetoxy group, a propionyloxy group, a butyryloxy group, an isobutyryloxy group. , pivaloyloxy group, pentanoyloxy group, hexanoyloxy group, heptanoyloxy group, octanoyloxy group, nonanoyloxy group, decanoyloxy group, undecanoyloxy group, dodecanoyloxy group and the like.
- C2-C10 acyloxy group is preferred, a C4-C8 acyloxy group is more preferred, and a C4-C6 acyloxy group is even more preferred.
- the “CX acyloxy group” means an acyloxy group having X carbon atoms including the carbon atoms constituting the carbonyl group.
- the term "cycloalkyl group” refers to a cyclic hydrocarbon group, for example, a C3 -C10 alkyl groups, preferably C3-C8 alkyl groups, etc., more preferably C3-C6 alkyl groups, etc., more preferably C3-C4 alkyl groups, etc.
- cycloalkyl-alkyl group refers to an alkyl group substituted with one cycloalkyl group.
- the "cycloalkyl-alkyl group” includes a cycloalkyl-alkyl group in which the cycloalkyl portion is the aforementioned cycloalkyl group and the alkyl portion is the aforementioned alkyl group.
- C4-C10 cycloalkyl-alkyl groups are preferred, and C4-C6 cycloalkyl-alkyl groups are preferred.
- C4-C10 cycloalkyl-alkyl group refers to a cycloalkyl-alkyl group in which the total number of carbon atoms in the cycloalkyl portion and the alkyl portion is 4-10. More specifically, cycloalkyl-alkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclohexylmethyl, cyclononylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 3-cyclopropylpropyl, 6-cyclo Examples include propylhexyl and the like, and cyclopropylmethyl and the like are preferred.
- alkyl-cycloalkyl group indicates a cycloalkyl group substituted with one alkyl group.
- the "alkyl-cycloalkyl group” includes an alkyl-cycloalkyl group in which the alkyl moiety is the aforementioned alkyl group and the cycloalkyl moiety is the aforementioned cycloalkyl group.
- a C4-C10 alkyl-cycloalkyl group is preferred, and a C4-C6 alkyl-cycloalkyl group is preferred.
- the “C4-C10 alkyl-cycloalkyl group” refers to an alkyl-cycloalkyl group in which the total number of carbon atoms in the alkyl portion and the cycloalkyl portion is 4-10. More specifically, alkyl-cycloalkyl groups include 1-methylcyclopropyl, 2-methylcyclopropyl, 1-methylcyclobutyl, 2-methylcyclohexyl, 4-methylcyclohexyl, 5-methylcyclononyl, 2- Ethylcyclopropyl, 2-propylcyclopropyl, 2-hexylcyclopropyl and the like, preferably 1-methylcyclopropyl, 2-methylcyclopropyl and the like. In general formula (1), R 1 may be the same or different, but are preferably the same.
- the ethylene group or trimethylene group represented by R 2 may be unsubstituted or substituted.
- the substituent is not particularly limited, and examples thereof include an alkyl group (eg, C1-C10 alkyl group).
- the number of such substituents is not limited, but for example, one R 2 preferably has one or two substituents.
- one R 2 has two substituents, it is preferable that two substituents are bonded to one carbon of methylene groups constituting an ethylene group or a trimethylene group.
- the "unsaturated hydrocarbon ring group” means a hydrocarbon ring group having at least one (preferably two or more) double bonds, an aryl group and a non-aromatic unsaturated hydrocarbon cyclic groups, and non-aromatic unsaturated hydrocarbon cyclic groups are preferred.
- unsaturated hydrocarbon ring groups include those having 5 to 10 carbon atoms.
- the number of double bonds possessed by the unsaturated hydrocarbon ring group is also not limited, but may be, for example, 1 to 5, preferably 2 to 4.
- the "aryl group” is a monovalent group obtained by removing one hydrogen from the aromatic ring of an aromatic hydrocarbon, for example, a monocyclic or bicyclic group having 6 to 10 carbon atoms such as a naphthyl group. and an aryl group of
- non-aromatic unsaturated hydrocarbon ring group refers to an unsaturated hydrocarbon ring group other than an aryl group, and has 5 to 10 carbon atoms (preferably 6 to 8 carbon atoms). Cyclic or bicyclic (preferably monocyclic) may be mentioned. The number of double bonds possessed by the non-aromatic unsaturated hydrocarbon ring group is also not limited, but may be, for example, 1 to 4, preferably 2 to 3.
- cyclopentenyl group More specifically, for example, cyclopentenyl group, cyclopenta-2,4-dienyl group, cyclohexa-2,4-dienyl group, cyclohepta-2,4,6-trienyl group, 1H-indenyl group, 1, 2-dihydronaphthyl group and the like.
- the "heterocyclic group” includes, for example, 1 to 9 carbons (preferably 1 to 7, more preferably 2 to 5, still more preferably 2 to 4) and oxygen, sulfur and at least one heteroatom (preferably 1 to 3, more preferably 2) selected from the group consisting of nitrogen, monocyclic or bicyclic (preferably monocyclic) saturated or unsaturated Saturated (preferably saturated) heterocycles are included. Sulfur is preferred as the heteroatom contained in the heterocyclic ring.
- the heterocyclic ring for example, a 4- to 10-membered ring is preferable, and a 4- to 6-membered ring is more preferable.
- heterocyclic rings include, for example, dithietanyl, dithiolanyl, tetrahydrofuranyl, tetrahydrothiophenyl, tetrazolidinyl, pyrrolidinyl, morpholinyl, pyridinyl, piperidinyl, dithianyl, furanyl, thiophenyl groups, quinolinyl groups, and the like.
- the unsaturated hydrocarbon ring group and/or heterocyclic group may have a substituent.
- substituents include an alkyl group, an oxo group, a hydroxy group, an alkoxy group, an amino group, an amine group, a halogen group and the like, and an alkyl group, an oxo group and the like are preferred.
- those substituents may be the same or different.
- the number of substituents is not limited, and examples thereof include at least 1, 1 to 3, 1 to 2, and the like.
- R 1 is an optionally substituted unsaturated hydrocarbon ring group
- the "optionally substituted unsaturated hydrocarbon ring group” is aromatic (electrons are delocalized like a resonance structure). Therefore, in this embodiment, preferable examples of the "optionally substituted unsaturated hydrocarbon ring group” include an aryl group; mentioned. Further, preferred examples of the "unsaturated hydrocarbon ring group optionally having a substituent” include a group in which one or more hydrogen atoms of a non-aromatic unsaturated hydrocarbon ring group are substituted with the above substituents. and those that have come to exhibit aromaticity are also included. Preferable unsaturated hydrocarbon ring groups having substituents include 5-isopropyl-7-oxocyclohepta-1,3,5-trienyl group and the like.
- amine group refers to an amino group having one or two alkyl groups, aryl groups, etc. as substituents.
- the two substituents may be the same or different.
- compound (1) is used as an antineoplastic agent, more specifically a prodrug of an antineoplastic agent. Therefore, in the present invention, compound (1) is inhibited from hydrolysis in blood (release of the active ingredient from the prodrug molecule by cleavage of the carbonate moiety) and is hydrolyzed in tumor cells to release the active ingredient. It is preferred to produce certain SN-38 or derivatives thereof.
- ClogP is preferably 5.0 to 14.0, more preferably 7.0 to 12.0.
- ClogP is the octanol/water partition coefficient LogP calculated from the structural formula of the target compound using the "CLogP" program of ChemDraw Professional 16.0.
- Table 1 below shows the CLogP values for some representative compounds of the present invention.
- SN-38 dimer (SS, carbonate) indicates a compound in which both R 1 are hydroxy groups and both R 2 are ethylene groups in the above general formula (1).
- SN-38xC a dimer (SS, carbonate) in the above table means a compound in which both R 1 are acyloxy groups having a carbon number and both R 2 are ethylene groups in the above general formula (1). show.
- SN-38xC 2 dimer (SS, carbonate) indicates a compound in which both R 1 are acetoxy groups and both R 2 are ethylene groups in the above general formula (1).
- compound (1) include dimers of the following groups:
- the term "salt” means a pharmaceutically acceptable salt.
- the salt of compound (1) includes an acid addition salt and a salt with a base.
- acid addition salts include inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, perchlorate, and phosphate, oxalate, malonate, and succinic acid.
- salts maleate, fumarate, lactate, malate, citrate, tartrate, benzoate, trifluoroacetate, acetate, methanesulfonate, p-toluenesulfonate, trifluoromethane
- examples include organic acid salts such as sulfonates, and acidic amino acid salts such as glutamate and aspartate.
- Specific examples of salts with bases include alkali metal or alkaline earth metal salts such as sodium salts, potassium salts or calcium salts, salts with organic bases such as pyridine salts and triethylamine salts, and bases such as lysine and arginine. and salts with synthetic amino acids.
- compound (1) or a salt thereof may exist in the form of hydrates or solvates, these hydrates and solvates are also included in the compounds that are active ingredients of the present invention.
- compounds of the present invention have isomers such as geometric isomers, stereoisomers, and optical isomers, these isomers are included in the compounds of the present invention unless otherwise specified.
- Solvents that form solvates include water, alcohols such as ethanol and propanol, organic acids such as acetic acid, esters such as ethyl acetate, ethers such as tetrahydrofuran and diethyl ether, ketones such as acetone, and DMSO. exemplified.
- Compound (1) can be produced by various methods, but for example, it is produced by the method shown by the following reaction scheme. [Reaction formula-1]
- compound 2 can be obtained by first reacting compound 1 with triphosgene.
- the proportion of compound 1 and triphosgene used is not particularly limited, but for example, 0.3 to 0.4 mol of the latter can be used per 1 mol of the former.
- the reaction can be carried out in the presence of a base such as 4-dimethylaminopyridine (DMAP), triethylamine (TEA), pyridine and the like.
- DMAP 4-dimethylaminopyridine
- TAA triethylamine
- pyridine pyridine
- the reaction temperature of the above reaction is not particularly limited, and the reaction is usually carried out at room temperature, under cooling or heating. Preferably, it is 0 to 25°C.
- the reaction time of the above reaction is also not particularly limited, but the reaction can be carried out for, for example, 5 to 1 hour.
- compound (1') can be obtained by reacting compound 2 with 2,2'-disulfanediylbis(ethan-1-ol).
- the ratio of compound 2 and 2,2'-disulfanediylbis(ethan-1-ol) to be used is not particularly limited. can be used in Moreover, the reaction temperature of the above reaction is not particularly limited, and the reaction is usually carried out at room temperature, under cooling or heating. Preferably, it is 0 to 25°C.
- the reaction time of the above reaction is also not particularly limited, but the reaction can be carried out, for example, for 60 minutes to 24 hours. [Reaction formula-2]
- compound (1'') can be obtained by reacting compound 2 with 2,2'-disulfanediylbis(propan-1-ol).
- the ratio of the compound 1 and 2,2′-disulfanediylbis(propan-1-ol) to be used is not particularly limited, but for example, the former is in the range of 0.4 to 0.5 mol per 1 mol of the former.
- the reaction temperature of the above reaction is not particularly limited, and the reaction is usually carried out at room temperature, under cooling or heating. Preferably, it is 0 to 25°C.
- the reaction time of the above reaction is also not particularly limited, but the reaction can be carried out, for example, for 60 minutes to 24 hours.
- Nanoparticles The present invention provides nanoparticles containing compound (1) or a salt thereof.
- nanoparticles refer to particles having an average particle size of less than 1 ⁇ m.
- the nanoparticles of the invention are generally spherical.
- the average particle size in the present invention can be measured by a scanning electron microscope (SEM) or dynamic light scattering method (DLS).
- SEM scanning electron microscope
- DLS dynamic light scattering method
- the nanoparticles of the present invention preferably have an average particle size of 10 to 500 nm, more preferably 10 to 100 nm.
- the nanoparticles of the present invention can typically be prepared by injecting a solution of compound (1) or a salt thereof in a water-miscible organic solvent into water and dispersing it by the method described below.
- the nanoparticles of the present invention are organic nanocrystals of compound (1) or a salt thereof, and thus consist essentially of compound (1) or a salt thereof.
- the nanoparticles of the present invention contain components other than compound (1) or salts thereof (for example, additives for the water-miscible organic solvent used in the method for producing nanoparticles). may contain.
- the content of compound (1) or a salt thereof in the nanoparticles of the present invention is preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 99.9% by mass or more.
- the nanoparticles of the present invention can be produced by a method including the step of injecting a solution of compound (1) or a salt thereof in a water-miscible organic solvent into water.
- a solution of compound (1) or a salt thereof in a water-miscible organic solvent is injected into water using a syringe.
- the water-miscible organic solvent is not particularly limited as long as it is a good solvent for compound (1) or a salt thereof.
- Acetone, tetrahydrofuran, ethanol, dimethylsulfoxide and the like are preferable from the viewpoint of solubility and safety. These solvents can be used singly or in combination.
- the content of compound (1) or its salt in the water-miscible organic solvent solution of compound (1) or its salt is not particularly limited, but is, for example, 0.1 to 15% by mass, preferably 0.1 to 10% by mass. It can be set appropriately within the range of %.
- Polysorbate 80 (PS80), polyvinylpyrrolidone (PVP), etc. may be added to the water-miscible organic solvent solution in addition to compound (1) or a salt thereof.
- the amount of the water-miscible organic solvent solution of compound (1) or a salt thereof to be injected into water is not particularly limited. .1-0.2 ml can be added.
- the injection time is not particularly limited, but for example, the injection is preferably performed for 0.1 to 1 second, more preferably 0.1 to 0.2 seconds.
- the temperature of the reaction system in this step is also not particularly limited, but can be set appropriately in the range of, for example, 0 to 30°C, preferably 10 to 20°C.
- the stirring speed is not particularly limited, but can be appropriately set, for example, in the range of 1000 to 1500 rpm, preferably 1200 to 1500 rpm.
- the temperature in the stirring step is the same as in the injection step.
- the stirring time is not particularly limited, but can be appropriately set, for example, in the range of 1 to 10 seconds, preferably 1 to 3 seconds.
- Injection of a water-miscible organic solvent solution into water and optional stirring crystallizes or particulates compound (1) or a salt thereof, resulting in an aqueous dispersion of nanoparticles of compound (1) or a salt thereof. can be obtained.
- the nanoparticles obtained can be used as a dispersion while being dispersed in water.
- the water-miscible organic solvent used for dissolving compound (1) or a salt thereof and adding it to water is preferably removed before use from the viewpoint of safety.
- a method for removing the organic solvent is not particularly limited, and a known method can be used.
- the organic solvent can be removed by distillation under reduced pressure (or normal pressure), dialysis, or the like.
- the obtained nanoparticles can also be used after being isolated as a fine particle powder by subjecting the dispersion to a solid-liquid separation operation such as filtration.
- a solid-liquid separation operation such as filtration.
- the description of Patent Document 1 can be referred to.
- the compound of the present invention or a salt thereof is preferable because a high-concentration dispersion (for example, 0.1 to 10 mM, preferably 1 to 10 mM dispersion) can be obtained when nanoparticles are formed as described above.
- the present invention provides a pharmaceutical containing compound (1) or a salt thereof.
- the present invention also provides a medicament containing the nanoparticles of the present invention described above.
- various pharmaceutically acceptable carriers e.g., tonicity agents, chelating agents, stabilizers, pH adjusters, preservatives, , antioxidants, solubilizers, thickening agents, etc.
- the pharmaceutical of the present invention can be used for prevention or treatment of cancer.
- the cancer to be prevented or treated is not particularly limited, but preferably includes solid tumors, specifically esophageal cancer, stomach cancer, colon cancer, colorectal cancer, rectal cancer, and pancreatic cancer. , liver cancer, laryngeal cancer, lung cancer, prostate cancer, bladder cancer, breast cancer, uterine cancer or ovarian cancer.
- the target site is a tumor cell, tissue, organ or organ and the inside thereof.
- tonicity agents examples include sugars such as glucose, trehalose, lactose, fructose, mannitol, xylitol and sorbitol; polyhydric alcohols such as glycerin, polyethylene glycol and propylene glycol; sodium chloride, potassium chloride and calcium chloride; Inorganic salts etc. are mentioned.
- chelating agents include edetate salts such as disodium edetate, disodium calcium edetate, trisodium edetate, tetrasodium edetate, and calcium edetate, ethylenediaminetetraacetate, nitrilotriacetic acid or salts thereof, and hexamethalin. acid sodium, citric acid, and the like.
- edetate salts such as disodium edetate, disodium calcium edetate, trisodium edetate, tetrasodium edetate, and calcium edetate, ethylenediaminetetraacetate, nitrilotriacetic acid or salts thereof, and hexamethalin. acid sodium, citric acid, and the like.
- stabilizers examples include sodium hydrogen sulfite.
- pH adjusters include acids such as hydrochloric acid, carbonic acid, acetic acid, and citric acid, and alkali metal hydroxides such as sodium hydroxide and potassium hydroxide, alkali metal carbonates such as sodium carbonate, and hydrogen carbonate. salts, alkali metal acetates such as sodium acetate, alkali metal citrates such as sodium citrate, and bases such as trometamol;
- antiseptics examples include sorbic acid, potassium sorbate, methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, paraoxybenzoate such as butyl parahydroxybenzoate, chlorhexidine gluconate, benzalkonium chloride, chloride quaternary ammonium salts such as benzethonium and cetylpyridinium chloride, alkylpolyaminoethylglycine, chlorobutanol, polyquad, polyhexamethylene biguanide, chlorhexidine and the like.
- antioxidants include sodium hydrogen sulfite, dried sodium sulfite, sodium pyrosulfite, concentrated mixed tocopherols, and the like.
- solubilizing agents include sodium benzoate, glycerin, D-sorbitol, glucose, propylene glycol, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, D-mannitol, etc.
- thickening agents include polyethylene glycol, methylcellulose, ethylcellulose, carmellose sodium, xanthan gum, sodium chondroitin sulfate, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol and the like.
- the pharmaceutical composition may further contain a compound known to have an antitumor effect, in addition to compound (1) or a salt thereof.
- chemotherapeutic agents such as podophyllotoxin (PPT), doxorubicin (DOX), fluorouracil (5-FU).
- the content of compound (1) or a salt thereof in the composition is not particularly limited, and in terms of the content of compound (1), for example, 90% by mass or more, 70% by mass or more, It can be appropriately set from conditions such as 50% by mass or more, 30% by mass or more, 10% by mass or more, 5% by mass or more, and 1% by mass or more.
- Formulations are not particularly limited, and examples include tablets, pills, capsules, powders, granules, syrups, sublingual preparations for oral administration; injections (intravenous injections, intramuscular injections, local injections, etc.), mouthwashes. , drops, external preparations (ointments, creams, patches, inhalants), and parenteral preparations such as suppositories.
- injections intravenous injections
- intramuscular injections intramuscular injections, local injections, etc.
- mouthwashes e.
- drops external preparations (ointments, creams, patches, inhalants), and parenteral preparations such as suppositories.
- parenteral preparations such as suppositories.
- preferable examples include injections (intravenous injections) and infusions.
- compound (1) or a salt thereof is useful because it exhibits an antitumor effect even when administered by direct injection into a tumor.
- the content of the compound (1) of the present invention in the formulation varies depending on the route of administration, patient age, body weight, symptoms, etc., and cannot be categorically defined. More preferably, the amount should be about 100 to 1000 mg. In the case of administration once a day, this amount should be contained in one preparation, and in the case of administration three times a day, one third of this amount should be contained in one preparation.
- the pharmaceutical of the present invention is administered to patients such as mammals.
- Mammals include humans, monkeys, mice, rats, rabbits, cats, dogs, pigs, cows, horses, sheep and the like.
- SN-38 ⁇ C6 (106.2 mg, 0.216 mmol), 4,4′-disulfanediyldibutyric acid (27.9 mg, 0.117 mmol), 1-ethyl-3-(3-dimethyl) were placed in an eggplant flask equipped with a stirrer bar.
- Aminopropyl)carbodiimide hydrochloride (175.1 mg, 0.913 mmol) and 4-dimethylaminopyridine (9.1 mg, 0.0745 mmol) were added and dissolved in 2.2 mL of dichloromethane.
- SN-38 ⁇ C6 50 mg, 0.1 mmol
- triphosgene 12 mg, 0.04 mmol
- 4-dimethylaminopyridine 61 mg, 0.5 mmol
- 2,2-dithiodiethanol dissolved in 1 mL of dichloromethane was added dropwise.
- the mixture was diluted with chloroform and washed with water and saturated aqueous sodium chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the solvent was distilled off under reduced pressure.
- compound B (22 mg, 46 %) was obtained as a pale yellow solid.
- compound B may also be indicated as compound SNC6DC.
- Example 2 Preparation method of nanoparticles of compounds A and B of the present invention 100 ⁇ L of THF solution of compounds A and B prepared to 10 mM is injected into 10 mL of water using a syringe at room temperature, stirred for 2 seconds at 1500 rpm, and nanoparticles are prepared. was obtained. The final aqueous dispersion concentration was 0.1 mM. SEM and DLS revealed a particle size of about 100 nm. SEM of the nanoparticles of compound B obtained above is shown in FIG.
- Test example 1 In Vitro Activity Test Human liver cancer cell line HePG2 or human breast cancer cell line KPL-4 was seeded in a 96-well plate at 2 ⁇ 10 4 cells/well. The next day, irinotecan, SN-38 derivatives (compound A ((SN-38xC 6 dimer (SS, ester)), compound B (SN-38xC 6 dimer (SS, carbonate))) nanoparticle dispersion, 0.04 ⁇ It was added to the HepG2 cell culture medium at 10 ⁇ M, cultured for 48 hours, and the cell viability was measured by colorimetric method using Cell Counting Kit-8 (manufactured by DOJINDO) and a microplate reader.
- SN-38 derivatives compound A ((SN-38xC 6 dimer (SS, ester)
- compound B SN-38xC 6 dimer (SS, carbonate)
- Boc-SN-38 (1476 mg, 3.00 mmol), triphosgene (356 mg, 1.20 mmol), 4-dimethylaminopyridine (1830 mg, 15.0 mmol), 2-hydroxyethyl disulfide (193 mg) were added to an eggplant flask equipped with a stirrer bar. , 1.25 mmol) was added and dissolved in 50 mL of dichloromethane at 0°C. After stirring at 0° C. for 1 hour, triphosgene (178 mg, 0.600 mmol) and 2-hydroxyethyl disulfide (193 mg, 1.25 mmol) were added.
- Example 6 Compounds SNC3DC, SNC4DC, SNC8DC, SNC10DC, SNC5DC of the present invention - (A), (B), (C), (D), (E), (F), (G), (H), (I) Production method
- SN0DC 200 mg, 0.202 mmol
- 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 78 mg, 0.502 mmol
- 4-dimethylaminopyridine 5 mg, 0.502 mmol
- SN0DC 200 mg, 0.202 mmol
- 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 78 mg, 0.502 mmol
- 4-dimethylaminopyridine 5 mg, 0.502 mmol
- Propionic acid 37 mg, 0.499 mmol
- was added stirred at room temperature for 3 hours, diluted with chloroform, and washed with water and saturated aqueous sodium chloride solution.
- SNC4DC The method for producing SNC3DC was the same except that SNC0DC (500 mg, 0.504 mmol) and butyric acid (110 mg, 1.25 mmol) were used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol). to give the title compound. Yield 62%.
- SNC8DC Same as the method for producing SNC3DC, except that SNC0DC (100 mg, 0.101 mmol) and octanoic acid (58 mg, 0.402 mmol) are used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol). to give the title compound. Yield 50%.
- SNC10DC SNC3DC (103.2 mg, 0.104 mmol) and capric acid (52.1 mg, 0.302 mmol) were used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol).
- the title compound was obtained in analogy to the preparation method. Yield 59%.
- SNC5DC-(A) The method for producing SNC3DC described above, except that SNC0DC (200 mg, 0.202 mmol) and 1-Methylcyclopropanecarboxylic acid (50 mg, 0.499 mmol) are used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol).
- SNC0DC 200 mg, 0.202 mmol
- 1-Methylcyclopropanecarboxylic acid 50 mg, 0.499 mmol
- SN0DC 200 mg, 0.202 mmol
- propionic acid 37 mg, 0.499 mmol
- SNC5DC-(B) Except for using SNC0DC (200 mg, 0.202 mmol) and 2-methylcyclopropane-1-carboxylic acid (50 mg, 0.499 mmol) instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol), The title compound was obtained in a manner similar to that of SNC3DC. Yield 71%.
- SNC5DC-(C) except that SNC0DC (200 mg, 0.202 mmol) and (R)-2-methylbutanoic acid (51 mg, 0.499 mmol) were used in place of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol).
- SNC0DC 200 mg, 0.202 mmol
- R -2-methylbutanoic acid
- SN0DC 200 mg, 0.202 mmol
- propionic acid 37 mg, 0.499 mmol
- SNC5DC-(E) Same as the above SNC3DC production method, except that SNC0DC (200 mg, 0.202 mmol) and pentanoic acid (51 mg, 0.499 mmol) are used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol). to give the title compound. Yield 58%.
- SNC5DC-(F) The method for producing SNC3DC described above, except that SNC0DC (200 mg, 0.202 mmol) and 3-methylbutanoic acid (51 mg, 0.499 mmol) are used in place of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol).
- SNC0DC 200 mg, 0.202 mmol
- 3-methylbutanoic acid 51 mg, 0.499 mmol
- SN0DC 200 mg, 0.202 mmol
- propionic acid 37 mg, 0.499 mmol
- SNC5DC-(G) Same as the above SNC3DC production method, except that SNC0DC (200 mg, 0.202 mmol) and Pivalic acid (51 mg, 0.499 mmol) are used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol). to give the title compound. Yield 26%.
- SNC5DC-(H) The method for producing SNC3DC, except that SNC0DC (200 mg, 0.202 mmol) and 2-cyclopropylacetic acid (50 mg, 0.499 mmol) are used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol).
- SNC0DC 200 mg, 0.202 mmol
- 2-cyclopropylacetic acid 50 mg, 0.499 mmol
- SN0DC 200 mg, 0.202 mmol
- propionic acid 37 mg, 0.499 mmol
- SNC5DC-(I) Same as the method for producing SNC3DC, except that SNC0DC (200 mg, 0.202 mmol) and cyclobutanecarboxylic acid (50 mg, 0.499 mmol) are used instead of SN0DC (200 mg, 0.202 mmol) and propionic acid (37 mg, 0.499 mmol). to give the title compound. Yield 65%.
- Example 9 Method for Producing High-Concentration Nanoparticles 750 ⁇ L of a THF solution of compound SNC4DC adjusted to 46.7 mM was injected into 4.25 mL of water using a syringe at room temperature to obtain an aqueous dispersion of nanoparticles. The final aqueous dispersion concentration was 7 mM. The same amount of polysorbate 80 as the compound is added when preparing the THF solution. After THF was removed, the volume was again measured to 5 mL, and mixed with a 9% aqueous sodium chloride solution at a ratio of 9:1.
- Test example 2 In Vitro Activity Test As in Test Example 1, human colon adenocarcinoma cell line HCT-116 was seeded in a 96-well plate at 2 ⁇ 10 4 cells/well. On the next day, SN-38 and each SN-38 derivative nanoparticle dispersion were added to the cell culture solution at 0.04 to 10 ⁇ M. After that, the cells were cultured for 48 hours, and cell viability was measured by a colorimetric method using Cell Counting Kit-8 (manufactured by DOJINDO) and a microplate reader. The results are shown in Table 2 below. As shown in Table 2 above, each compound of the present invention showed different IC50 values depending on the substituents. Based on the above results, the following Test Examples 3 and 4 were performed using SNC4DC, which has the highest pharmacological activity among the nanoparticles produced in FIG.
- SNC4DC NPDs indicates the SNC4DC nanoparticles obtained in Example 9. Tumor size was measured using vernier calipers.
- the results of the in vivo antitumor activity test are shown in FIG. As shown in Figure 5, SNC4DC NPDs exhibited higher antitumor activity compared to Irinotecan.
- FIG. 6 shows changes in body weight over time in each test plot. As shown in FIG. 6, no significant weight loss was observed with SNC4DC NPDs administration. Therefore, no serious toxicity was observed with SNC4DC NPDs administration.
- Test example 4 In Vitro Activity Test As in Test Example 1, human colon adenocarcinoma cell line HCT-116 or human mammary epithelial cell line HMEC was seeded in a 96-well plate at 2 ⁇ 10 4 cells/well. The next day, SN-38 and SN-38 derivative (SNC4DC) nanoparticle dispersions were added to the cell culture medium at 0.04-10 ⁇ M. After that, the cells were cultured for 48 hours, and cell viability was measured by a colorimetric method using Cell Counting Kit-8 (manufactured by DOJINDO) and a microplate reader. The IC50 results for cell viability are shown in Table 4 below. As shown in Table 4, SN-38 was highly toxic to normal cells, whereas SNC4DC was less toxic to normal cells.
- SNC4DC SN-38 and SN-38 derivative
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2021年3月12日に出願された、日本国特許出願第2021-40799号明細書(その開示全体が参照により本明細書中に援用される)に基づく優先権を主張する。本発明はSN-38誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法に関する。
項1.下記一般式(1)で表される化合物又はその塩。
項2.ClogPが5.0~14.0である、項1に記載の化合物又はその塩。
本発明は、下記一般式(1)で表される化合物又はその塩を提供する:
本発明において、炭素含有有機基としては、1~20個、好ましくは2~17個の炭素を有する有機基等が挙げられる。炭素含有有機基は、酸素、硫黄及び窒素からなる群より選択される少なくとも1個のヘテロ原子を有していてもよい。より具体的には、炭素含有有機基としては、アルキル基、アルコキシ基、-O-C(=O)-L-R3(式中、Lは単結合又はリンカー基を示す。R3は置換基を有してもよい不飽和炭化水素環基又は複素環基を示す)、-O-C(=O)-(Y)n-R4(式中、Yは窒素原子又は酸素原子を示す。nは0又は1を示す。R4はC2~C10のアルキル基、C3~C10のシクロアルキル基、C4~C10のシクロアルキル-アルキル基又はC4~C10のアルキル-シクロアルキル基を示す)等が挙げられる。一般式-O-C(=O)-L-R3で表される炭素含有有機基としては、例えば、5-(1,2-ジチオラン-3-イル)ペンタノイルオキシ基等が挙げられる。-O-C(=O)-(Y)n-R4で表される炭素含有有機基としては、例えば、アシルオキシ基、シクロアルキルカルボニルオキシ基、シクロアルキルアルキルカルボニルオキシ基、アルキルシクロアルキルカルボニルオキシ基、アルキルカルバモイルオキシ基、アルコキシカルボニルオキシ基等が挙げられる。
本発明において、アシルオキシ基とは、直鎖又は分子鎖状(好ましくは直鎖状)の飽和炭化水素が結合したカルボニルオキシ基を示し、例えば、アセトキシ基、プロピオニロキシ基、ブチリロキシ基、イソブチリロキシ基、ピバロイロキシ基、ペンタノイロキシ基、ヘキサノイロキシ基、ヘプタノイロキシ基、オクタノイロキシ基、ノナノイロキシ基、デカノイロキシ基、ウンデカノイロキシ基、ドデカノイロキシ基等が挙げられる。本発明においては、C2~C10アシルオキシ基が好ましく、C4~C8アシルオキシ基がより好ましく、C4~C6アシルキシ基がさらに好ましい。本発明において、「CXアシルオキシ基」とは、カルボニル基を構成する炭素原子も含めた炭素数がX個であるアシルオキシ基を意味する。従って、例えば、アセトキシ基(-O-C(=O)-CH3)はC2アシルオキシ基であり、ウンデカノイロキシ基(-O-C(=O)-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH2-CH3)はC11アシルオキシ基である。
本発明において「シクロアルキル基」とは、環状の炭化水素基を示し、例えば、シクロプロピル基、シクロブチル基、シクロペンチル基、シクロヘキシル基、シクロヘプチル基、シクロオクチル基、シクロノニル基、シクロシル基等のC3-C10アルキル基が挙げられ、好ましくはC3-C8アルキル基等が挙げられ、より好ましくはC3-C6アルキル基等が挙げられ、より好ましくはC3-C4アルキル基等が挙げられる。
本発明において「シクロアルキル-アルキル基」は、1個のシクロアルキル基で置換がされたアルキル基を示す。「シクロアルキル-アルキル基」としては、シクロアルキル部分が前述のシクロアルキル基であり、かつアルキル部分が前述のアルキル基であるシクロアルキル-アルキル基が挙げられる。本発明においては、C4-C10のシクロアルキル-アルキル基が好ましく、C4-C6のシクロアルキル-アルキル基が好ましい。本発明において、「C4-C10のシクロアルキル-アルキル基」とは、シクロアルキル部分とアルキル部分との炭素数の合計が4~10であるシクロアルキル-アルキル基を示す。より具体的には、シクロアルキル-アルキル基としては、シクロプロピルメチル、シクロブチルメチル、シクロヘキシルメチル、シクロノニルメチル、1-シクロプロピルエチル、2-シクロプロピルエチル、3-シクロプロピルプロピル、6-シクロプロピルヘキシル等が挙げられ、シクロプロピルメチル等が好ましい。
本発明において「アルキル-シクロアルキル基」は、1個のアルキル基で置換がされたシクロアルキル基を示す。「アルキル-シクロアルキル基」としては、アルキル部分が前述のアルキル基であり、かつシクロアルキル部分が前述のシクロアルキル基であるアルキル-シクロアルキル基が挙げられる。本発明においては、C4-C10のアルキル-シクロアルキル基が好ましく、C4-C6のアルキル-シクロアルキル基が好ましい。本発明において、「C4-C10のアルキル-シクロアルキル基」とは、アルキル部分とシクロアルキル部分との炭素数の合計が4~10であるアルキル-シクロアルキル基を示す。より具体的には、アルキル-シクロアルキル基としては、1-メチルシクロプロピル、2-メチルシクロプロピル、1-メチルシクロブチル、2-メチルシクロヘキシル、4-メチルシクロヘキシル、5-メチルシクロノニル、2-エチルシクロプロピル、2-プロピルシクロプロピル、2-ヘキシルシクロプロピル等が挙げられ、1-メチルシクロプロピル、2-メチルシクロプロピル等が好ましい。
一般式(1)において、R1は同一又は異なってもよいが、同一であることが好ましい。
置換基を有する不飽和炭化水素環基としては、好ましくは、5-イソプロピル-7-オキソシクロヘプタ-1,3,5-トリエニル基等が挙げられる。
[反応式-1]
反応式-1においては、まず、化合物1とトリホスゲンとを反応させることにより、化合物2を得ることができる。化合物1とトリホスゲンとの使用割合は特に限定されないが、例えば、前者1モルに対し後者を0.3~0.4モルで使用することができる。当該反応は、4-ジメチルアミノピリジン(DMAP)、トリエチルアミン(TEA)、ピリジン等の塩基の存在下で行うことができる。また、上記反応の反応温度は特に限定されず、通常、室温、冷却又は加熱下で反応が行われる。好ましくは、0~25℃等が挙げられる。上記反応の反応時間も特に限定されないが、例えば、5~1時間反応させることができる。
[反応式-2]
これらの反応は、通常、反応に悪影響を及ぼさない慣用の溶媒、例えば、ジクロロメタン、トリエチルアミン、アセトン、メチルエチルケトン、テトラヒドロフラン、ジオキサン、ジエチルエーテルジグライム、アセトニトリル、N,N-ジメチルホルムアミド、ジメチルスルホキシド等、これらの混合溶媒の中で行われる。
本発明は、化合物(1)又はその塩を含むナノ粒子を提供する。本発明においてナノ粒子とは、平均粒子径が1μm未満の粒子を示す。典型的な実施形態において、本発明のナノ粒子は、略球形である。本発明において平均粒子径は、走査型電子顕微鏡(SEM)又は動的光散乱法(DLS)により測定することができる。本発明のナノ粒子の平均粒子径は、好ましくは10~500nmであり、より好ましくは10~100nmである。本発明のナノ粒子は、典型的には、後述する方法により化合物(1)又はその塩の水混和性有機溶媒溶液を水に注入し、分散させることにより調製することができる。従って、典型的な実施形態において、本発明のナノ粒子は、化合物(1)又はその塩の有機ナノ結晶であるため、実質的に化合物(1)又はその塩のみからなる。ただし、本発明の効果が得られる範囲において、本発明のナノ粒子は、化合物(1)又はその塩以外の成分(例えば、ナノ粒子の製法に用いた水混和性有機溶媒に対する添加物等)を含んでいてもよい。例えば、本発明のナノ粒子における化合物(1)又はその塩の含有量は95質量以上が好ましく、99質量%以上がより好ましく、99.9質量%以上がより好ましい。
本発明は、化合物(1)又はその塩を含む医薬を提供する。また本発明は、前述した本発明のナノ粒子を含む医薬を提供する。
粘稠化剤としては、例えば、ポリエチレングリコール、メチルセルロース、エチルセルロース、カルメロースナトリウム、キサンタンガム、コンドロイチン硫酸ナトリウム、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、ポリビニルアルコール等が挙げられる。
1H-NMR (CDCl3, 400 MHz): δ= 0.956 (6H, t, J = 7 Hz), 1.38-1.44 (7H, m), 1.82 (2H,quin, J = 5.6 Hz), 2.05-2.11 (1H, m), 2.17-2.22 (1H, m), 2.66 (2H, t, J = 7.4 Hz), 2.78 (2H, t, J = 6.2 Hz),3.15 (2H, q, J = 7.7Hz), 3.88-4.00 (2H, m), 5.26-5.32 (2H, m), 5.35 (1H, d, J = 17 Hz), 5.8 (1H, d, J = 17 Hz), 7.21 (1H, s), 7.55 (1H, dd, J = 9.2, 2.4 Hz), 7.82 (1H, d, J = 2.4 Hz), 8.17 (1H, d, J = 9.2 Hz).
本発明の化合物A~Bのナノ粒子の作製方法
10mMに調製した化合物A~BのTHF溶液100μLを水10mL中に注射器を用いて室温下注入し、2秒間、1500rpmで攪拌して、ナノ粒子の水分散液を得た。最終的な水分散液の濃度は、0.1mMとなった。SEM及びDLSにより粒径が約100nmであることが明らかになった。上記で得られた化合物Bのナノ粒子のSEMを図2に示す。
in vitro活性試験
ヒト肝癌細胞株HePG2またはヒト乳癌細胞株KPL-4を96ウェルプレートに2×104cells/ウェルで播種した。翌日、イリノテカン、SN-38誘導体(化合物A((SN-38xC6 dimer (S-S, ester))、化合物B(SN-38xC6 dimer (S-S, carbonate)))ナノ粒子分散液を、0.04~10μMとなるようにHepG2細胞培養液に添加した。その後48時間培養し、Cell Counting Kit-8(DOJINDO社製)とマイクロプレートリーダーを用いて、比色法により細胞生存率を測定した。
本発明の化合物SNBocDCの製造方法
1H-NMR (CDCl3, 400 MHz): δ= 0.949 (3H, t, J = 7.4 Hz), 1.39 (3H, t, J = 7.8 Hz), 1.60 (9H, s), 2.03-2.23 (2H, m), 2.77 (2H, t, J = 6.2 Hz), 3.15 (q, J = 7.7 Hz), 3.85-4.00 (2H, m), 5.25 (2H, d, J = 5.6 Hz), 5.34 (1H, d, J = 17.2 Hz), 5.80 (1H, d, J = 17.2 Hz), 7.20 (1H, s), 7.65 (1H, dd, J = 9.2, 2.4 Hz), 7.89 (1H, d, J = 2.4 Hz), 8.16 (1H, d, J = 9.2 Hz).
本発明の化合物SNC0DCの製造方法
1H-NMR (DMSO, 400 MHz): δ= 0.881 (3H, t, J =7.4 Hz), 1.26 (3H, t, J = 7.6 Hz), 2.08-2.15 (2H, m), 2.90-2.99 (2H, m), 3.04 (2H, q, J = 7.5 Hz), 5.23 (2H,s). 5.5 (2H, d, J = 3.2 Hz), 6.91 (1H, s). 7.36-7.38 (2H, m), 7.96 (1H, d, J = 10 Hz), 10.3 (1H, br).
本発明の化合物SNC2DCの製造方法
1H-NMR (CDCl3, 400 MHz): δ= 0.953 (3H, t, J = 7.4 Hz), 1.37 (3H, t, J = 7.6 Hz), 2.03-2.25 (2H, m), 2.40 (3H, s), 2.78 (2H, t, J = 6.2 Hz), 3.14 (2H, q, J = 7.7 Hz), 3.87-4.02 (2H, m), 5.25 (2H, d, J = 5.2 Hz), 5.34 (1H, d, J = 17.2 Hz), 5.78 (1H, d, J = 16.8 Hz), 7.20 (1H, s), 7.55 (1H, dd, J = 9.2, 2.8 Hz), 7.82 (1H, d, J = 2.4 Hz), 8.16 (1H, d, J = 9.2 Hz).
本発明の化合物SNC3DC、SNC4DC、SNC8DC、SNC10DC、SNC5DC-(A)、(B)、(C)、(D)、(E)、(F)、(G)、(H)、(I)の製造方法
スターラーバーを備えたナスフラスコにSN0DC(200mg、0.202mmol)、1-エチル-3-(3-ジメチルアミノプロピル)カルボジイミド塩酸塩(78mg、0.502mmol)、4-ジメチルアミノピリジン(5mg、0.0409mmol)を入れ、ジクロロメタン8.0mLに溶解させた。プロピオン酸(37mg、0.499mmol)を入れ、室温で3時間撹拌後、クロロホルムで希釈し、水及び飽和塩化ナトリウム水溶液を用いて洗浄した。有機層を無水硫酸マグネシウムで乾燥後、ろ過、溶媒の減圧留去により得られた残渣を、シリカゲルカラムクロマトグラフィー(クロロホルム→クロロホルム/アセトン=5:1)で精製して化合物SNC3DC(91.4mg、41%)を淡黄色固体として得た。
1H-NMR (CDCl3, 400 MHz): δ= 0.945 (3H, t, J = 7.6 Hz), (3H, t, J = 7.6 Hz), 1.39 (3H, t, J = 7.6 Hz), 2.03-2.12 (1H, m), 2.16-2.25 (1H, m), 2.69 (2H, q, J = 7.5 Hz), 2.78 (2H, t, J = 6.2 Hz), 3.14 (2H, q, J = 7.7 Hz), 3.87-4.02 (2H, m), 5.25 (2H, d, J = 4.8 Hz), 5.33 (1H, d, J = 17.2 Hz), 5.78 (1H, d, J = 17.2 Hz), 7.20 (1H, s), 7.54 (1H, dd, J = 9.0, 2.4 Hz), 7.82 (1H, d, J = 2.4 Hz), 8.16 (1H, d, J = 8.8 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(500mg、0.504mmol)及び酪酸(110mg、1.25mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率62%。
1H-NMR (CDCl3, 400 MHz): δ= 0.958 (3H, t, J = 7.4 Hz), 1.10 (3H, t, J = 7.4 Hz), 1.40 (3H, t, J = 7.4 Hz), 1.81-1.90 (2H, m), 2.05-2.12 (1H, m), 2.17-2.24 (1H, m), 2.65 (2H, t, J = 7.4 Hz), 2.78 (2H, t, J = 6.2 Hz), 3.15 (2H, q, J = 7.6 Hz), 3.87-3.93 (1H, m), 3.96-4.02 (1H, m), 5.27 (2H, d, J = 4.8 Hz), 5.30 (1H, d, J = 17.2 Hz), 5.80 (1H, d, J = 17.2 Hz), 7.21 (1H, s), 7.55 (1H, dd, J = 9.2, 2.4 Hz), 7.56 (1H, d, J = 2.4 Hz), 8.17 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(100mg、0.101mmol)及びオクタン酸(58mg、0.402mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率50%。
1H-NMR (CDCl3, 400 MHz): δ= 0.905 (3H, t, J = 6.8 Hz), 0.957 (3H, t, J = 7.4 Hz), 1.31-1.42 (11H, m), 1.77-1.83 (2H, m), 2.05-2.24 (2H, m), 2.66 (2H, t, J = 7.6 Hz), 2.78 (2H, t, J = 6.2 Hz), 3.15 (2H, q, J = 7.7 Hz), 3.88-4.00 (2H, m), 5.26 (2H, d, J = 5.2 Hz), 5.35 (1H, d, J = 17.2 Hz), 5.80 (1H, d, J = 17.2 Hz), 7.21 (1H, s), 7.55 (1H, dd, J = 9.2, 2.4 Hz), 7.82 (1H, d, J = 2.8 Hz), 8.17 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(103.2mg、0.104mmol)及びカプリン酸(52.1mg、0.302mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率59%。
1H-NMR (CDCl3, 400 MHz): δ= 0.873 (3H, t, J = 7.0 Hz), 0.944 (3H, t, J = 7.6 Hz), 1.27-1.5 (15H, m), 1.76-1.82 (2H, m), 2.03-2.09 (1H, m), 2.17-2.23 (1H, m), 2.65 (2H, t, J = 7.6 Hz), 2.76 (2H, t, J = 6.2 Hz), 3.14 (2H, q, J = 7.7 Hz), 3.85-3.90 (1H, m), 3.93-3.98 (1H, m), 5.24 (2H, d, J = 5.2 Hz), 5.33 (1H, d, J = 17.2 Hz), 5.79 (1H, d, J = 17.2 Hz), 7.19 (1H, s), 7.53 (1H, dd, J = 9.2, 2.4 Hz), 7.80 (1H, d, J = 2.4 Hz), 8.15 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及び1-Methylcyclopropanecarboxylic acid(50mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率65%。
1H-NMR (CDCl3, 400 MHz): δ= 0.941-0.960 (5H, m), 1.38 (3H, t, J = 7.7 Hz), 1.48-1.51 (5H, m), 2.02-2.24 (2H, m), 2.77 (2H, t, J = 6.2 Hz), 3.13 (2H, q, J = 7.6 Hz), 3.86-4.01 (2H, m), 5.24 (2H, d, J = 4.4 Hz), 5.33 (1H, d, J = 17.2 Hz), 5.77 (1H, d, J = 17.2 Hz), 7.19 (1H, s), 7.51 (1H, dd, J = 9.2, 2.4 Hz), 7.78 (1H, d, J = 2.4 Hz), 8.14 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及び2-methylcyclopropane-1-carboxylic acid(50mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率71%。
1H-NMR (CDCl3, 400 MHz): δ= 0.914-0.961 (4H, m), 1.23 (3H, d, J = 5.6 Hz), 1.31-1.41 (5H, m), 1.62-1.65 (1H, m), 2.04-2.23 (2H, m), 2.77 (2H, t, J = 6.2 Hz), 3.13 (2H, q, J = 7.6 Hz), 3.88-3.99 (2H, m), 5.23 (2H, d, J = 4.4 Hz), 5.33 (1H, d, J = 17.1 Hz), 5.77 (1H, d, J = 17.1 Hz), 7.19 (1H, s), 7.54 (1H, dd, J = 9.2, 2.4 Hz), 7.81 (1H, d, J = 2.4 Hz), 8.14 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及び(R)-2-methylbutanoic acid(51mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率71%。
1H-NMR (CDCl3, 400 MHz): δ= 0.943 (3H, t, J = 7.4 Hz), 1.07 (3H, t, J = 7.4 Hz), 1.34-1.40 (6H, m), 1.67-1.72 (1H, m), 1.86-1.91 (1H, m), 2.06-2.21 (2H, m), 2.17-2.78 (3H, m), 3.14 (2H, q, J = 7.7 Hz), 3.86-3.96 (2H, m), 5.24 (2H, d, J = 5.2 Hz), 5.33 (1H, d, J = 17.1 Hz), 5.77 (1H, d, J = 17.1 Hz), 7.19 (1H, s), 7.52 (1H, dd, J = 9.2, 2.4 Hz), 7.79 (1H, d, J = 2.4 Hz), 8.15 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及び(S)-2-methylbutanoic acid(51mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率58%。
1H-NMR (CDCl3, 400 MHz): δ= 0.944 (3H, t, J = 7.5 Hz), 1.07 (3H, t, J = 7.4 Hz), 1.34-1.40 (6H, m), 1.67-1.72 (1H, m), 1.86-1. 93 (1H, m), 2.06-2.21 (2H, m), 2.17-2.78 (3H, m), 3.14 (2H, q, J = 7.7 Hz), 3.87-3.99 (2H, m), 5.24 (2H, d, J = 5.2 Hz), 5.33 (1H, d, J = 17.2 Hz), 5.77 (1H, d, J = 17.2 Hz), 7.19 (1H, s), 7.53 (1H, dd, J = 9.2, 2.4 Hz), 7.79 (1H, d, J = 2.4 Hz), 8.15 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及びPentanoic acid(51mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率58%。
1H-NMR (CDCl3, 400 MHz): δ= 0.929-1.01 (6H, m), 1.38 (3H, t, J = 7.7 Hz), 1.46-1.51 (2H, m), 1.75-1.83 (2H, m), 2.06-2.21 (2H, m), 2.65 (2H, t, J = 7.4 Hz), 2.77 (2H, t, J = 6.2 Hz), 3.14 (2H, q, J = 7.7 Hz), 3.87-3.99 (2H, m), 5.24 (2H, d, J = 5.2 Hz), 5.33 (1H, d, J = 17.1 Hz), 5.78 (1H, d, J = 17.1 Hz), 7.19 (1H, s), 7.53 (1H, dd, J = 9.2, 2.4 Hz), 7.80 (1H, d, J = 2.4 Hz), 8.15 (1H, d, J = 8.8 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及び3-methylbutanoic acid(51mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率56%。
1H-NMR (CDCl3, 400 MHz): δ= 0.945 (3H, t, J = 7.5 Hz), 1.10 (6H, d, J = 6.7 Hz), 1.38 (3H, t, J = 7.7 Hz), 2.04-2.33 (3H, m), 2.53 (2H, d, J = 7.1 Hz), 2.77 (2H, t, J = 6.2 Hz), 3.13 (2H, q, J = 7.7 Hz), 3.85-4.01 (2H, m), 5.24 (2H, d, J = 5.2 Hz), 5.33 (1H, d, J = 17.2 Hz), 5.78 (1H, d, J = 17.2 Hz), 7.19 (1H, s), 7.53 (1H, dd, J = 9.2, 2.4 Hz), 7.79 (1H, d, J = 2.4 Hz), 8.15 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及びPivalic acid(51mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率26%。
1H-NMR (CDCl3, 400 MHz): δ= 0.960 (3H, t, J = 7.5 Hz),1.40 (3H, t, J = 7.7 Hz), 1.44 (9H, s), 2.08-2.19 (2H, m), 2.78 (2H, t, J = 6.3 Hz), 3.16 (2H, q, J = 7.7 Hz), 3.90-4.01 (2H, m), 5.26 (2H, d, J = 5.0 Hz), 5.34 (1H, d, J = 17.2 Hz), 5.78 (1H, d, J = 17.2 Hz), 7.21 (1H, s), 7.51 (1H, dd, J = 9.2, 2.4 Hz), 7.79 (1H, d, J = 2.4 Hz), 8.17 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及び2-cyclopropylacetic acid(50mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率48%。
1H-NMR (CDCl3, 400 MHz): δ= 0.330 (2H, q, J = 5.1 Hz), 0.690 (2H, q, J = 5.1 Hz), 0.980 (3H, t, V J = 6.8 Hz), 1.21-1.25 (1H, m), 1.40 (3H, t, J = 7.7 Hz), 2.05-2.25 (2H, m), 2.57 (2H, d, J = 7.1 Hz), 2.79 (2H, t, J = 6.2 Hz), 3.16 (2H, q, J = 7.7 Hz), 3.89-4.01 (2H, m), 5.27 (2H, d, J = 5.4 Hz), 5.35 (1H, d, J = 17.2 Hz), 5.79 (1H, d, J = 17.2 Hz), 7.21 (1H, s), 7.57 (1H, dd, J = 9.2, 2.4 Hz), 7.85 (1H, d, J = 2.4 Hz), 8.18 (1H, d, J = 9.2 Hz).
SN0DC(200mg、0.202mmol)及びプロピオン酸(37mg、0.499mmol)に代えてSNC0DC(200mg、0.202mmol)及びcyclobutanecarboxylic acid(50mg、0.499mmol)を用いる以外、前記SNC3DCの製造方法と同様にして、標記化合物を得た。収率65%。
1H-NMR (CDCl3, 400 MHz): δ= 0.945 (3H, t, J = 7.5 Hz), 1.38 (3H, t, J = 7.7 Hz), 2.04-2.19 (4H, m), 2.37-2.52 (4H, m), 2.77 (2H, t, J = 6.2 Hz), 3.13 (2H, q, J = 7.6 Hz), 3.45-3.49 (1H, m), 3.91-3.97 (2H, m), 5.23 (2H, d, J = 4.6 Hz), 5.33 (1H, d, J = 17.2 Hz), 5.77 (1H, d, J = 17.2 Hz), 7.19 (1H, s), 7.53 (1H, dd, J = 9.2, 2.4 Hz), 7.81 (1H, d, J =2.4 Hz), 8.15 (1H, d, J = 9.2 Hz).
本発明の化合物SNC3NDC、SNC4NDCの製造方法
スターラーバーを備えたナスフラスコにSN0DC(263.9mg、0.266mmol)、1-isocyanatopropane(64.3mg、0.756mmol)、トリエチルアミン(127.5mg、1.26mmol)を入れ、ジクロロメタン5.0mLに溶解させた。室温で4時間撹拌後、クロロホルムで希釈し、水、飽和塩化アンモニウム水溶液及び飽和塩化ナトリウム水溶液を用いて洗浄した。有機層を無水硫酸マグネシウムで乾燥後、ろ過、溶媒の減圧留去により得られた残渣を、シリカゲルカラムクロマトグラフィー(クロロホルム→クロロホルム/アセトン=5:1)で精製して化合物SNC3NDC(92.8mg、30%)を淡黄色固体として得た。
1H-NMR (CDCl3, 400 MHz): δ= 0.951-1.03 (6H, m), 1.37 (3H, t, J = 7.6 Hz), 1.63-1.68 (2H, m), 2.79 (2H, t, J = 6.2 Hz), 3.11 (2H, q, J = 6.8 Hz), 3.29 (2H, q, J = 6.8 Hz), 3.94-3.97 (1H, m), 4.01-4.06 (1H, m), 5.22 (2H, d, J = 1.6 Hz), 5.32-5.37 (2H, m), 5.77 (1H, d, J = 17.2 Hz), 7.20 (1H, s), 7.56 (1H, dd, J = 9.2, 2.4 Hz), 7.84 (1H, d, J = 2.4 Hz), 8.12 (1H, d, J = 9.2 Hz).
SN0DC(263.9mg、0.266mmol)及び1-isocyanatopropane(64.3mg、0.756mmol)に代えてSNC0DC(255.4mg、0.258mmol)及び1-isocyanatobutane(75mg、0.757mmol)を用いる以外、前記SNC3NDCの製造方法と同様にして、標記化合物を得た。収率19%。
1H-NMR (CDCl3, 400 MHz): δ= 0.934-0.990 (6H, m), 1.34-1.46 (5H, m), 1.57-1.64 (2H, m), 2.05-2.10 (1H, m), 2.17-2.24 (1H, m), 2.79 (2H, t, J = 7.0 Hz), 3.07-3.13 (2H, m), 3.29-3.34 (2H, q, J = 6.6 Hz), 3.94-4.05 (2H, m), 5.21 (2H, d, J = 1.6 Hz), 5.32-5.36 (2H, m), 5.76 (1H, d, J = 17.2 Hz), 7.20 (1H, s), 7.55 (1H, dd, J = 9.2, 2.4 Hz), 7.83 (1H, d, J = 2.4 Hz), 8.11 (1H, d, J = 9.2 Hz).
SNCnDC(n=0,2,4,6,8,10)ナノ粒子の作製
10mMに調製した化合物のDMSOまたはTHF溶液100μLを水10mL中に注射器を用いて室温下注入し、2秒間、1500rpmで攪拌して、ナノ粒子の水分散液を得た。最終的な水分散液の濃度は、0.1mMとなった。SEM及びDLSによりn=0,2の場合にナノ粒子は即座に凝集することが明らかになった。n=4,6,8,10の場合に粒径が約100nmであることが明らかになった。上記で得られた化合物のナノ粒子のSEMを図3に示す。
高濃度のナノ粒子の作製方法
46.7mMに調製した化合物SNC4DCのTHF溶液750μLを水4.25mL中に注射器を用いて室温下注入し、ナノ粒子の水分散液を得た。最終的な水分散液の濃度は、7mMとなった。THF溶液を調製する際に化合物と同量のポリソルベート80を添加している。THFを除去した後に再度5mLになるよう定量し、9%塩化ナトリウム水溶液と9:1の割合で混合させ作製した。高濃度分散液の作製直後及び二ヶ月経過後のナノ粒子のSEM像の結果を図4右上の写真に示す。ナノ粒子の粒径分布の経時変化の結果を図4右下のグラフに示す。
in vitro活性試験
試験例1と同様に、ヒト結腸腺癌細胞株HCT-116を96ウェルプレートに2×104cells/ウェルで播種した。翌日、SN-38、各SN-38誘導体ナノ粒子分散液を、0.04~10μMとなるように細胞培養液に添加した。その後48時間培養し、Cell Counting Kit-8(DOJINDO社製)とマイクロプレートリーダーを用いて、比色法により細胞生存率を測定した。結果を下記表2に示す。
以上の結果から、図3で作製したナノ粒子の中で最も薬理活性の高いSNC4DCを用いて、以下の試験例3および試験例4を行った。
in vivo抗腫瘍活性試験
下記表3に示す条件で、ヒト結腸腺がん由来のHCT116細胞を担がんしたマウス(n=5)に対して、2日おきに計5回、100μLを微静脈注射により投与した。
腫瘍の大きさはノギスを用いて測定した。当該 in vivo抗腫瘍活性試験の結果を図5に示す。図5に示すように、Irinotecanと比較してSNC4DC NPDsは高い抗腫瘍活性を発揮した。また、各試験区における体重の経時的変化を図6に示す。図6に示すように、SNC4DC NPDs投与による有意な体重減少は見られなかった。従って、SNC4DC NPDs投与により深刻な毒性は確認されなかった。
in vitro活性試験
試験例1と同様に、ヒト結腸腺癌細胞株HCT-116またはヒト乳腺上皮細胞株HMECを96ウェルプレートに2×104cells/ウェルで播種した。翌日、SN-38、SN-38誘導体(SNC4DC)ナノ粒子分散液を、0.04~10μMとなるように細胞培養液に添加した。その後48時間培養し、Cell Counting Kit-8(DOJINDO社製)とマイクロプレートリーダーを用いて、比色法により細胞生存率を測定した。
細胞生存率のIC50の結果を下記表4に示す。
Claims (7)
- ClogPが5.0~14.0である、請求項1に記載の化合物又はその塩。
- R1が水素、ヒドロキシ基、-O-C(=O)-L-R3(式中、Lは単結合又はリンカー基を示す。R3は置換基を有してもよい不飽和炭化水素環基又は複素環基を示す)又は-O-C(=O)-(Y)n-R4(式中、Yは窒素原子又は酸素原子を示す。nは0又は1を示す。R4はC2~C10のアルキル基、C3~C10のシクロアルキル基、C4~C10のシクロアルキル-アルキル基又はC4~C10のアルキル-シクロアルキル基を示す)である、請求項1又は2に記載の化合物又はその塩。
- 請求項1~3のいずれか一項に記載の化合物又はその塩を含むナノ粒子。
- 請求項1~3のいずれか一項に記載の化合物又はその塩又は請求項4に記載のナノ粒子を含む医薬。
- 癌の予防又は治療のための請求項5に記載の医薬。
- 請求項1~3のいずれか一項に記載の化合物又はその塩の水混和性有機溶媒溶液を水に注入する工程を含む、ナノ粒子の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280020372.3A CN117015545A (zh) | 2021-03-12 | 2022-01-14 | Sn-38衍生物、包含该衍生物的纳米粒子、医药及该纳米粒子的制造方法 |
JP2023505158A JPWO2022190626A1 (ja) | 2021-03-12 | 2022-01-14 | |
AU2022234045A AU2022234045A1 (en) | 2021-03-12 | 2022-01-14 | Sn-38 derivative, nano-particles containing said derivative, medicine, and method for producing said nano-particles |
EP22766594.0A EP4306527A1 (en) | 2021-03-12 | 2022-01-14 | Sn-38 derivative, nano-particles containing said derivative, medicine, and method for producing said nano-particles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-040799 | 2021-03-12 | ||
JP2021040799 | 2021-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022190626A1 true WO2022190626A1 (ja) | 2022-09-15 |
Family
ID=83226544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/001163 WO2022190626A1 (ja) | 2021-03-12 | 2022-01-14 | Sn-38誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4306527A1 (ja) |
JP (1) | JPWO2022190626A1 (ja) |
CN (1) | CN117015545A (ja) |
AU (1) | AU2022234045A1 (ja) |
WO (1) | WO2022190626A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115844891A (zh) * | 2022-11-04 | 2023-03-28 | 沈阳药科大学 | 二硫键桥连的sn38二聚体前药及其自组装纳米粒、制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011155501A1 (ja) * | 2010-06-11 | 2011-12-15 | 独立行政法人科学技術振興機構 | 薬剤多量体微粒子及びその製造方法 |
CN107669626A (zh) * | 2017-09-03 | 2018-02-09 | 河南师范大学 | 一种高载药量的还原敏感的药物传递系统的制备方法及其应用 |
JP2021040799A (ja) | 2019-09-09 | 2021-03-18 | 西川 基守 | パチンコ遊技機 |
-
2022
- 2022-01-14 WO PCT/JP2022/001163 patent/WO2022190626A1/ja active Application Filing
- 2022-01-14 JP JP2023505158A patent/JPWO2022190626A1/ja active Pending
- 2022-01-14 EP EP22766594.0A patent/EP4306527A1/en active Pending
- 2022-01-14 AU AU2022234045A patent/AU2022234045A1/en active Pending
- 2022-01-14 CN CN202280020372.3A patent/CN117015545A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011155501A1 (ja) * | 2010-06-11 | 2011-12-15 | 独立行政法人科学技術振興機構 | 薬剤多量体微粒子及びその製造方法 |
CN107669626A (zh) * | 2017-09-03 | 2018-02-09 | 河南师范大学 | 一种高载药量的还原敏感的药物传递系统的制备方法及其应用 |
JP2021040799A (ja) | 2019-09-09 | 2021-03-18 | 西川 基守 | パチンコ遊技機 |
Non-Patent Citations (4)
Title |
---|
DONGXUAN HE, WEI ZHANG, HONGZHANG DENG, SHUAIDONG HUO, YI-FENG WANG, NINGQIANG GONG, LIANDONG DENG, XING-JIE LIANG, ANJIE DONG: "Self-assembling nanowires of an amphiphilic camptothecin prodrug derived from homologous derivative conjugation", CHEMICAL COMMUNICATIONS, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 52, no. 98, 1 January 2016 (2016-01-01), UK , pages 14145 - 14148, XP055727032, ISSN: 1359-7345, DOI: 10.1039/C6CC07595A * |
GUO XING, WANG LIN, DUVAL KAYLA, FAN JING, ZHOU SHAOBING, CHEN ZI: "Dimeric Drug Polymeric Micelles with Acid‐Active Tumor Targeting and FRET‐Traceable Drug Release", ADVANCED MATERIALS, VCH PUBLISHERS, DE, vol. 30, no. 3, 1 January 2018 (2018-01-01), DE , pages 1705436, XP055966441, ISSN: 0935-9648, DOI: 10.1002/adma.201705436 * |
JPN. J. APPL. PHYS., vol. 31, 1992, pages L1132 - L1134 |
WANG HUA, XU MING, XIONG MENGHUA, CHENG JIANJUN: "Reduction-responsive dithiomaleimide-based nanomedicine with high drug loading and FRET-indicated drug release", CHEMICAL COMMUNICATIONS, ROYAL SOCIETY OF CHEMISTRY, UK, vol. 51, no. 23, 1 January 2015 (2015-01-01), UK , pages 4807 - 4810, XP055966439, ISSN: 1359-7345, DOI: 10.1039/C5CC00148J * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115844891A (zh) * | 2022-11-04 | 2023-03-28 | 沈阳药科大学 | 二硫键桥连的sn38二聚体前药及其自组装纳米粒、制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117015545A (zh) | 2023-11-07 |
JPWO2022190626A1 (ja) | 2022-09-15 |
EP4306527A1 (en) | 2024-01-17 |
AU2022234045A1 (en) | 2023-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018171164A1 (zh) | 一种喜树碱类前药及其制备和应用 | |
TWI316942B (en) | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents | |
US20100010059A1 (en) | Anticancer oral formulation | |
CA3113463A1 (en) | Nitroxoline prodrug and use thereof | |
JP2008524218A (ja) | ゲムシタビンのアミドプロドラック、組成物、及びそれらの使用 | |
JP5620046B2 (ja) | テモゾロマイドエステルよりなる医薬組成物 | |
US20150119388A1 (en) | Novel pro- and codrug derivatives for nanoparticle delivery of select anticancer agents formed using rapidly cleavable phenolic ester bridges | |
WO2022190626A1 (ja) | Sn-38誘導体、当該誘導体を含むナノ粒子、医薬及び当該ナノ粒子の製造方法 | |
US9650390B2 (en) | Water-soluble taxane derivatives and uses thereof | |
AU2016415408B2 (en) | Rotigotine behenate, and preparation method and use thereof | |
KR101068259B1 (ko) | 헤테로사이클기에 고리-축합된 신규 베툴린산 유도체 | |
US20210115039A1 (en) | Cocrystal | |
WO2017024953A9 (zh) | 尼莫地平水溶性衍生物及其制备方法和应用 | |
JP5622856B2 (ja) | キサントン誘導体およびその用途 | |
WO2024122113A1 (ja) | 化合物、ナノ粒子、医薬、及びナノ粒子の製造方法 | |
WO2005061492A1 (ja) | 含窒素複素環化合物およびそれらを有効成分とする薬剤 | |
KR20180038697A (ko) | 지방산이 결합된 엔테카비어 유도체 화합물 및 이의 약학적 용도 | |
AU2016278040B2 (en) | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof | |
JP2021514353A (ja) | ベンゾジアゼピン誘導体塩酸塩および結晶形、その製造方法および用途 | |
JP2021147340A (ja) | 化合物、そのナノ粒子及び癌疾患の治療剤 | |
JPH06279432A (ja) | 新規な化合物および該化合物を有効成分とする抗癌剤 | |
TW202130619A (zh) | 硝羥喹啉前藥及其用途 | |
WO2018203564A1 (ja) | リファガールの類縁体、及びリファガール又はその類縁体を含む多標的キナーゼ阻害剤 | |
KR20220006305A (ko) | 2-(페닐티오)벤조[d]티아졸 유도체를 포함하는 항암용 조성물 | |
KR20110101488A (ko) | 올란자핀 지나포에이트염 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22766594 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023505158 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18548109 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2022234045 Country of ref document: AU Date of ref document: 20220114 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280020372.3 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022766594 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022766594 Country of ref document: EP Effective date: 20231012 |